Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

Company Overview - Agenus (AGEN) shares increased by 6.8% to close at $5.31, following a notable trading volume, despite a 55.8% loss over the past four weeks [1] - The company is expected to report a quarterly loss of $3.10 per share, reflecting a year-over-year increase of 29.6%, with revenues projected at $53.2 million, up 132.3% from the previous year [1] Clinical Data - Updated data from a phase I study on the BOT/BAL combination therapy for metastatic colorectal cancer showed a 12-month overall survival rate of 71% and an 18-month overall survival rate of 62% in patients with non-microsatellite instability-high (MSS) or deficient mismatch repair (dMMR) [1] Earnings Estimates - The consensus EPS estimate for Agenus has been revised 0.6% higher over the last 30 days, indicating a positive trend that may lead to price appreciation [2] - The stock currently holds a Zacks Rank of 3 (Hold) [2] Industry Context - Agenus operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Regeneron (REGN) [2] - Regeneron has seen a 0.3% increase in its stock price, but has returned -7.7% over the past month [2]